Table 4 Efficacy of CAG regimen in AML patients according to karyotypes
Study | Year | Total No. patients | No. Patients | No. CR | CR % | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Favorable | Intermediate | Unfavorable | Favorable | Intermediate | Unfavorable | Favorable | Intermediate | Unfavorable |
Saito [38] | 2000 | 63 | 6 | 27 | 30 | 5 | 19 | 9 | 83 | 70 | 29 |
Hirayama [39] | 2003 | 9 | 1 | 4 | 4 | 1 | 3 | 2 | 100 | 75 | 50 |
Qian [20] | 2007 | 40 | 2 | 28 | 10 | 1 | 19 | 4 | 50 | 68 | 40 |
Chen [46] | 2008 | 34* | 6 | 16 | 9 | 6 | 13 | 2 | 100 | 81 | 22 |
Zhu [50] | 2009 | 30 | 4 | 21 | 5 | 2 | 12 | 0 | 50 | 57 | 0 |
Ma [28] | 2010 | 31 | 3 | 18 | 10 | 1 | 14 | 2 | 33 | 78 | 20 |